Eidos Therapeutics Inc. (EIDX)

48.78
1.32 2.78
NASDAQ : Health Technology
Prev Close 47.46
Open 47.57
Day Low/High 46.70 / 49.30
52 Wk Low/High 8.89 / 48.92
Volume 174.42K
Avg Volume 187.80K
Exchange NASDAQ
Shares Outstanding 36.88M
Market Cap 1.70B
EPS -2.20
P/E Ratio 86.20
Div & Yield N.A. (N.A)

Latest News

Building Economic Strength: Cramer's 'Mad Money' Recap (Tuesday 8/20/19)

Building Economic Strength: Cramer's 'Mad Money' Recap (Tuesday 8/20/19)

Jim Cramer says if you want to see the U.S. economy's strength, look to Home Depot, where the consumer's confidence and influence remains healthy.

Canopy Growth, Okta, B&G Foods: 'Mad Money' Lightning Round

Canopy Growth, Okta, B&G Foods: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Canopy Growth, Okta, B&G Foods, Eidos Therapeutics, Select Medical Holdings and more.

Eidos Therapeutics Confirms Receipt Of Non-Binding Proposal From BridgeBio Pharma To Acquire Shares

Eidos Therapeutics Confirms Receipt Of Non-Binding Proposal From BridgeBio Pharma To Acquire Shares

Eidos Therapeutics, Inc. (Nasdaq:EIDX) (the "Company") today confirmed that it has received a non-binding proposal dated August 8, 2019 (the "Proposal") from BridgeBio Pharma, Inc.

Eidos Therapeutics Reports Second Quarter 2019 Financial Results

Eidos Therapeutics Reports Second Quarter 2019 Financial Results

SAN FRANCISCO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc.

EIDX Crosses Above Average Analyst Target

EIDX Crosses Above Average Analyst Target

In recent trading, shares of Eidos Therapeutics Inc have crossed above the average analyst 12-month target price of $38.28, changing hands for $39.17/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

RM LAW Announces An Investigation Of Eidos Therapeutics, Inc.

RM LAW Announces An Investigation Of Eidos Therapeutics, Inc.

BERWYN, Pa., April 5, 2019 /PRNewswire/ --  RM LAW, P.

INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Eidos Therapeutics, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Eidos Therapeutics, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Eidos Therapeutics, Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Eidos Therapeutics, Inc. - EIDX

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Eidos Therapeutics, Inc. - EIDX

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Eidos Therapeutics, Inc.

Eidos Therapeutics Is Now Oversold (EIDX)

Eidos Therapeutics Is Now Oversold (EIDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Why Red-Hot IPO Market Will Soon Bring Financial Carnage

Why Red-Hot IPO Market Will Soon Bring Financial Carnage

The day of reckoning could be lurking for the market because of trends in the red-hot IPO market. Be prepared.

3 'Pound the Table' Calls for Stock Market Caution

3 'Pound the Table' Calls for Stock Market Caution

Misplaced confidence, IPO mania and historically high valuations mean it's increasingly important for investors to recognize potential negatives on the investment horizon.